How integration across biology, technology, and policy is shaping the future of cancer research

The 2026 American Association of Cancer Research (AACR) Annual Meeting took place in San Diego from April 17-22 and reflected how cancer research continues to evolve. Progress is increasingly driven by how advances across biology, technology, and policy come together to shape how we understand disease, develop new treatments, and bring them into practice.

The meeting featured a number of important scientific developments that point to a few broader themes about where the field is headed. Below are a few highlights and what they may mean for patients, researchers, and the future of cancer care.

Cancer as a System: Expanding How We Understand Disease

A central theme this year was the continued focus on cancer as more than just a collection of tumor cells. It is shaped by a complex ecosystem — immune cells, surrounding tissue, metabolism, and even the microbiome — all interacting in dynamic ways.

Researchers are also interested in how nerves influence tumors. Rather than being passive bystanders, nerve signals can actively shape immune responses and suppress anti-tumor activity, adding a layer that may help explain why some tumors resist treatment. In certain tumor types, cancer cell invasion into nerve structures has even emerged as a potential predictor of immunotherapy response.

Immunotherapy: From Breakthrough to Precision

Immunotherapy has transformed cancer care, and the field is now shifting from broad activation of the immune system to more precise and predictable approaches, targeting the right patients, tumor features, and immune pathways at the right time.

A key theme at AACR 2026 was a deeper focus on why immune responses fail. Even when immune cells are present, tumors can create conditions that push those cells into a dysfunctional state, reframing resistance as a dynamic state that may be reversible.

Cell therapies such as chimeric antigen receptors (CAR) T-cell therapy continue to demonstrate the potential of immune-based approaches. The AACR-ASCO Joint Session showcased ongoing efforts to expand CAR T- and other engineered cell therapies into solid tumors, where efficacy has remained one of the field’s most persistent challenges. These next-generation approaches aim to improve durability, targeting, and safety.

Immunotherapy is also moving from disease treatment to prevention. Studies in oral precancer, led by investigators at The University of Texas MD Anderson Cancer Center, showed that direct injection of nivolumab (Opdivo®) reduced lesion size by an average of 60%, with more than 80% of lesions remaining cancer-free after one year. This approach could reduce the need for more invasive interventions while preserving function and quality of life.

Clinical progress is also emerging beyond immunotherapy alone. Therapies targeting tumors with KRAS mutations — once considered “undruggable” — are beginning to show promising results in pancreatic and lung cancers, with data from Revolution Medicines pointing to new possibilities in some of the field’s most challenging diseases.

Work presented at AACR by CRI Research Scientist Fahad Benthani, PhD, further revealed how the clinical landscape is evolving. Analyses of more than 24,000 global immunotherapy trials show increasing diversity in therapeutic approaches and combination strategies, along with shifts in how biomarkers guide development.

Technology: Enabling Discovery and Development

While much of the progress in cancer research is driven by advances in biology and therapeutics, technology is playing an increasingly important role in enabling discovery.

Artificial intelligence is now being used across the research pipeline, from drug discovery to trial design, helping analyze data and identify patterns more quickly and consistently. At the same time, new platforms from companies such as 10x Genomics are enabling researchers to analyze tumors at single-cell resolution and within their spatial context, offering a more detailed view of how cancer and immune cells interact.

New approaches to modeling disease — how we mimic cancer development and progression — are also emerging. Experimental models, such as organoids and patient-derived xenografts, as well as computational approaches, can complement traditional methods with the potential to make research more predictive of human outcomes.

Policy and Infrastructure: Enabling Progress at Scale

Even as scientific progress accelerates, structural challenges continue to shape how — and how quickly — innovation reaches patients. Discussions at the AACR Researcher Town Hall underscored continued uncertainty in federal research funding as well as increasing global competition.

Clinical trials sit at the center of this challenge. While they are essential to developing new therapies, they remain slow to launch and difficult for many patients to access.

A poster by CRI’s Director of Strategic Programs, Cynthia Neben, PhD, demonstrated both the scale of this challenge and the opportunity to improve it. Efforts to enable greater access to clinical trials and increase patient enrollment could significantly expand participation and ensure that advances in immunotherapy reach the patients who may benefit most.

Looking Ahead: From Discovery to Integration

The overarching message from AACR 2026 is clear: cancer research is moving from a focus on individual discoveries to a focus on integration, connecting biology, technology, and policy to deliver real-world impact. This progress reflects the work of a broad community of researchers, including members of the CRI network who contributed findings across basic immunology, translational science, and clinical research at this year’s meeting.

The science continues to advance rapidly. The opportunity now is to ensure that progress reaches patients — faster, more equitably, and with greater precision.

The path ahead is not just discovering what is possible. It is making it work in practice.